Literature DB >> 26469786

Interaction between HLA-B60 and HLA-B27 as a Better Predictor of Ankylosing Spondylitis in a Taiwanese Population.

James Cheng-Chung Wei1, Henry Wong Sung-Ching2, Yu-Wen Hsu3, Ya-Feng Wen4, Wen-Chang Wang5, Ruey-Hong Wong6, Hsing-Fang Lu7, Floris A van Gaalen8, Wei-Chiao Chang9.   

Abstract

OBJECTIVE: Ankylosing spondylitis (AS) is a form of chronic inflammatory spondyloarthritis (SpA) that causes pain and stiffness in spines or joints. Human leukocyte antigen B27 (HLA-B27) and B60 (HLA-B60) have been reported as major genetic risk factors of AS. In addition, rs13202464, located on major histocompatibility complex (MHC) region, showed high sensitivity (98.7%) and specificity (98.0%) for HLA-B27.
DESIGN: The aim of our study is to test whether the interaction between HLA-B60 and HLA-B27 (rs13202464) can serve as a better predictor of AS. We have genotyped HLA-B60 and rs13202464 among 471 patients with AS and 557 healthy subjects. Combined risk factors were investigated to test the biological interaction.
RESULTS: Our results indicated that the relative risk (RR) for HLA-B27+/HLA-B60- was 152 (95% CI 91 to 255) and it increased to 201 (95% CI 85 to 475) in HLA-B27+/HLA-B60+ patients (with HLA-B27-/HLA-B60- as reference). Combinational analysis of two risk factors (HLA-B27+/HLA-B60+) showed a relative excess risk due to interaction (RERI) of 46.79 (95% CI: -117.58 to 211.16), attributable proportion (AP) of 0.23 (95% CI: -0.41 to 0.88) and a synergy index (S) of 1.31 (95% CI: 0.56 to 3.04).
CONCLUSION: In conclusion, genetic interaction analysis revealed that the interaction between HLA-B60 and HLA-B27 is a better marker for the risk of AS susceptibility in a Taiwanese population.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26469786      PMCID: PMC4607494          DOI: 10.1371/journal.pone.0137189

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Ankylosing spondylitis (AS) is a chronic inflammatory disease leading to pain, stiffness and possible fusion of spinal segments. It is considered as a chronic, inflammatory disorder and affects sacroiliac joints, lumbar spine, and peripheral joints [1]. Progression of disease in AS patients often leads to limited of mobility, functional impairment and finally affects the patients’ well-being [2]. Prevalence of AS in men is higher than in women [3], while the pathological mechanisms of AS remain unclear [4]. A genome-wide association study (GWAS) conducted by The Australo-Anglo-American Spondyloarthritis Consortium (TASC) revealed the association of HLA-B27, IL-23 and IL-1 genes to AS [5]. HLA-B27 gene is the best-known genetic susceptibility marker for AS, however, it only explains for 16% of the genetic variability in AS [6,7]. Associations between AS and the HLA-B27 gene and HLA-B60 gene have also been revealed [8]. In addition, Wei et al. showed that HLA-B60 is a risk factor for HLA-B27 negative patients [9]. In 2013, epistasis between HLA-B27 and HLA-B60 has been reported to associate with increased risk of AS in Caucasians, with a very high relative excess risk [10]. rs13202464, located on major histocompatibility complex (MHC) region, showed high sensitivity (98.7%) and specificity (98.0%) to for HLA-B27 [11]. Another GWAS in Han populations also indicated that rs13202464 of HLA-B can represent the risk effects of HLA-B27 in a Chinese population [6]. In this study, we investigated the correlation between HLA-B27 and HLA-B60 and the risk of AS. The association between HLA-B27/HLA-B60 and disease severity of AS was also tested.

Materials and Methods

Subject recruitment

The patients with AS and the healthy subjects were from the Chung Shan Medical University Hospital. All of the participants recruited were ethnic Taiwanese. AS patients who met the New York AS diagnosis criteria were recruited to participate. Our study was approved by the institutional review boards of the Chung Shan Medical University Hospital in Taichung, Taiwan. Informed consent was obtained and be written before any data were collected from the subjects. Our study was approved by the institutional review boards of the Chung Shan Medical University Hospital in Taichung, Taiwan. Informed consent was obtained and be written before any data were collected from the subjects. This study has included the patients with age below 18 years old, with youngest subjects enrolled with age 17. These patients are considered adults by our Ethics Committee, and also the informed consent was obtained and be written before any data were collected from these subjects. The Bath AS Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), and Bath AS Global (BAS-G) which evaluate disease activity, physical function, and global well-being is collected by questionnaire. Modified Chinese versions of the BASDAI, BASFI, and BAS-G showed good intra-class correlations and Cronbach’s alpha values.

DNA extraction and HLA Genotyping

DNA of blood cells were extracted by first treating them with 0.5% sodium dodecylsulfate lysis buffer and then protease K (1 mg/ml) to digest nuclear proteins for 4 h at 60°C. Total DNA was harvested using a Gentra (Qiagen, Valencia, CA) extraction kit followed by 70% alcohol precipitation. DNA purification from buffy coat was carried out by using the Gentra Puregene Blood Kit (Qiagen, Valencia, CA, USA). rs13202464 (HLA-B27) were genotyped by using the TaqMan® Allelic Discrimination Assay (Applied Biosystems, Foster City, CA). HLA-B60 positivity is identified by two separated SYBR Green real-time PCRs. A 96-well micro-plate with an ABI9700 Thermal Cycler (Applied Biosystems) is used to perform polymerase chain reaction (PCR). After PCR, fluorescence was detected and analyzed by StepOne software vers. 2.2.2 (Applied Biosystems) [12].

Data analysis

Previous studies showed that genotypes of rs13202464 can tag to HLA-B27. Thus, we classified all subjects into HLA-B27 positive (GG and AG genotype) or negative (AA genotype) by rs13202464 genotypes [11]. To examine the interaction effect between HLA-B27 and HLA-B60, samples were categorized into four groups: HLA-B27+/HLA-B60+, HLA-B27+/HLA-B60-, HLA-B27-/HLA-B60+, HLA-B27-/HLA-B60- based on the genotyping results. The odds ratios (ORs) were calculated to assess the additivity of interaction effect, which use the sample of HLA-B27-/HLA-B60- as reference. The prevalence of AS in Taiwan is rare (0.167%) according to the definition of World Health Organization and this satisfies a rare disease assumption thereby replacing RRs with ORs. We used CaTS to calculate the power of association between HLA-B27/B60 to AS susceptibility [13]. Interaction is defined as a departure from additivity of effects. Three indices have been used to evaluate the biological interaction between HLA-B27 and HLA-B60: (1) RERI: the relative excess risk due to interaction. (2) AP: the proportion of disease among those with two risk factors that is attributable to its interaction. (3) S: synergy index. RERI and AP should be zero and S should be 1 when no interaction was detected between two exposures. To obtain the parameter estimates needed for calculating these three measures, a logistic regression model was fitted [14]. The Statistical Package for the Social Sciences (SPSS) V. 20.0 (SPSS, Chicago, Illinois, USA) and R software (http://cran.r-project.org/), were used to analyse the data. Package epiR was used for biological interaction analysis. In all tests, p values less than 0.05 were considered significant.

Results

As shown in Table 1, a total of 1028 subjects were recruited including 471 patients with AS, and 557 healthy subjects. The number of male in AS patients and normal subjects was 320 (67.9%) and 435 (78.0%). The mean of age in both groups were 39.0 years. HLA-B27 and HLA-B60 genotype data were collected from both patients and control subjects. Four hundred and thirty one (91.5%) AS patients and forty three (7.7%) control subjects were categorized as HLA-B27+. Besides, the number of HLA-B60+ was one hundred (21.3%) and seventy three (13.1%), respectively. The ORs of HLA-B27 and HLA-B60 to AS have been 120.80 (95% CI = 83.31 to 204.82) and 1.79 (95% CI = 1.29 to 2.49), respectively (Table 2).
Table 1

Basal characteristics of patients with ankylosing spondylitis (AS) and control subjects.

CharacteristicsPatients with ASControl subjects
Number of subjects471557
Gender: male (No (%))320 (67.9%)435 (78.0%)
Age (years) a 39.0 ± 11.339.0 ± 12.2
Range17–8217–77
HLA-B27(+)431 (91.5%)43 (7.7%)
HLA-B60(+)100 (21.3%)73 (13.1%)

aMean ± SD. SD:standard deviation.

Table 2

HLA association with AS in Taiwanese population.

AS no (%)Controls no (%)OR (95% CI)
HLA-B27+431 (91.5%)43 (7.7%)120.80 (83.31–204.82)*
HLA-B27-40 (8.5%)514 (92.2%)
All471 (100%)557 (100%)
HLA-B60+100 (21.3%)73 (13.1%)1.79 (1.29–2.49)*
HLA-B60-371 (78.7%)484 (87.1%)
All471 (100%)557 (100%)

*p<0.001. No, number of individuals.

aMean ± SD. SD:standard deviation. *p<0.001. No, number of individuals. We further assessed the independent effect and gene-gene interaction effect of HLA-B27 and HLA-B60 to AS susceptibility by categorizing our samples into four strata: HLA-B27+/HLA-B60+, HLA-B27+/HLA-B60-, HLA-B27-/HLA-B60+, HLA-B27-/HLA-B60-. Samples with HLA-B27-/HLA-B60- were considered as reference. As the prevalence of AS is relatively rare in Asian (0.167%), odds ratio was calculated to substitute relative risk in this study. Fig 1 showed that both HLA-B27 and HLA-B60 were disease-susceptibility gene for AS, with odds ratio (OR) 152 (95% confidence interval (CI) 91 to 255, Fisher’s-exact p = 0.0072) and OR 2.9 (95% CI 1.4 to 6.0, Fisher’s exact p = 1.222×10−157) respectively. With HLA-B27−/HLA-B60− as the reference, patient who carried both HLA-B27 and HLA-B60 (HLA-B27+/HLA-B60+) showed a high susceptibility to AS, with the OR increased to 201 (95%CI 85 to 475, Fisher’s exact p = 2.5007×10−69). Besides, CaTS power calculator revealed an expected power for a one stage study of 1.000 for both genetic risk factors to the AS susceptibility.
Fig 1

Interaction between HLA-B60 and HLA-B27 in ankylosing spondylitis susceptibility in a Taiwanese population with contribution of the different genes to the odds ratio (OR) marked.

1Odds ratio is calculated by unconditional maximum likelihood estimation and 95% confidence intervals are calculated using normal approximation (Wald method). 2 P-value is calculated by Fisher-exact test. AS: ankylosing spondylitis; CI: confidence interval; No: number of individuals; OR: odds ratio.

Interaction between HLA-B60 and HLA-B27 in ankylosing spondylitis susceptibility in a Taiwanese population with contribution of the different genes to the odds ratio (OR) marked.

1Odds ratio is calculated by unconditional maximum likelihood estimation and 95% confidence intervals are calculated using normal approximation (Wald method). 2 P-value is calculated by Fisher-exact test. AS: ankylosing spondylitis; CI: confidence interval; No: number of individuals; OR: odds ratio. To confirm the independent effect of HLA-B27and HLA-B60 to AS susceptibility, logistic regression analysis were performed and the result indicated that two genetic risk factors were independent for the susceptibility of AS (HLA-B27: P-value < 0.001 and HLA-B27 P-value = 0.0148) (Table 3).
Table 3

Logistic regression analysis to identify the independency of two risk factors HLA-B27 and HLA-B60.

CoefficientsEstimate ßStandard error P-value
Intercept-2.69140.1795 <0.001**
HLA-B27 4.87940.2326 <0.001**
HLA-B60 0.74930.3074 0.0148*

Significant (p<0.05) value is in bold* and p<0.001 is in bold**.

Significant (p<0.05) value is in bold* and p<0.001 is in bold**. The risk for AS in HLA-B27+/HLA-B60+ exceeded the sum of the risks (201 > (152+2.9)) in HLA-B27−/HLA-B60+ and HLA-B27+/HLA-B60− (Fig 1) but not the product of the risks (201 < (152×2.9)). Calculated biological interaction measures show a departure from additivity of the two risk factors combined (HLA-B27+/HLA-B60+) with a RERI of 46.79 (95% CI: -117.58 to 211.16), AP of 0.23 (95% CI: -0.41 to 0.88) and S of 1.31 (95% CI: 0.56 to 3.04). These results implied the positive gene-gene interaction effects between HLA-B27 and HLA-B60 in a Taiwanese population. In order to investigate the association between HLA antigens and AS severity, further analysis was conducted. We investigated whether HLA-B27 or HLA-B60 associated with clinical phenotypes including Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Bath Ankylosing Spondylitis Global Index (BAS-G), which represent disease activity, physical function, and global well-being respectively. Although a deviation form additivity of HLA-B27 and HLA-B60 to AS susceptibility has been detected, neither association between HLA-B27 nor HLA-B60 and AS disease severity was observed (Table 4).
Table 4

Difference in the scores of BASDAI, BASFI, and BAS-G among AS patients stratified by different HLA-B27/ HLA-B60 genotype.

No.BASDAIBASFIBAS-G
HLA-B27 + /HLA-B60 +884.37 ± 2.20 a 2.17 ± 2.334.17 ± 2.79
HLA-B27 + /HLA-B603344.28 ± 2.162.02 ± 2.194.30 ± 2.73
HLA-B27 –/HLA-B60 +124.72 ± 1.611.64 ± 1.403.65 ± 2.26
HLA-B27 –/HLA-B60254.94 ± 2.582.60 ± 2.324.91 ± 3.05
P-value b 0.51560.52050.3995

aData represent means ± S.D.

bP-value was calculated by Kruskal-Wallis rank sum test.

aData represent means ± S.D. bP-value was calculated by Kruskal-Wallis rank sum test.

Discussion

HLA has been known to involve in the antigen recognition process and is a well-known susceptibility factor for the pathogenesis of AS. HLA-B27 is considered as the major susceptibility factor of AS [8,14,15]. HLA-B27 is a highly polymorphic gene, with 105 subtypes: HLA-B*27:01 to HLA-B*27:106 [16,17]. Indeed, comparison of HLA-B27−/HLA-B60− group and HLA-B27+/HLA-B60− group (Fig 1), our results confirmed that HLA-B27 plays an important role in the risk of AS in Taiwanese patients. To measure biological interaction between HLA-B27 and HLA-B60, we calculated three parameters that measure the departure from additivity of risk effects of each risk factor, i.e. RERI, the relative excess risk due to attributable to HLA-B27 and HLA-B60 interaction; AP[AB], the proportion of AS among those with both exposures that is attributable to HLA-B27 and HLA-B60 interaction; and synergy index, which measures the interaction between two risk factors expressed as the ratio of relative excess risk for the combined effect of the risk factors and the sum of the relative excess risks for each separate effect of the two risk factors. In our study, odds ratio was calculated to estimate the value of risk ratio, and further, calculate the value of RERI, AP and S. Our results showed a departure from additivity of the two risk factors combined (HLA-B27+/HLA-B60+) with a RERI of 46.79 (95% CI: -117.58 to 211.16), AP of 0.23 (95% CI: -0.41 to 0.88) and S of 1.31 (95% CI: 0.56 to 3.04). The RERI, AP and S indices showed a positive additive interaction, indicating that the combination effects of HLA-B27 and HLA-B60. HLA-B27 and HLA-B60 genes are located on chromosome 6p21.3, both coding proteins involve in antigen presenting functions. HLA presents endogenous antigens to T-cells and further triggers the autoimmune responses. Recent studies suggested that peptide motifs of HLA-B60 may different from HLA-B27 [18-20], thus these HLA-B subtypes might involve in different antigen-triggered pathologic pathways. Therefore, the epistatic effects between HLA-B27 and HLA-B60 may be due to the similar downstream T-cell mediated immune responses. Kirsten Falk et al. (1995) proposed that the peptide binding motif of HLA-B60 is different from HLA-B27 [20], thus it is unlikely that HLA-B27 and HLA-B60 can bind with the same AS pathogenic peptides and trigger disease onset9. However, López D et al. (1994) showed the cross-reactions of T cell epitope from CTL clones between HLA-B27 with HLA-B60/61 [21]. Thus, similar T-cell epitopes may be a key factor to explain the epistatic effects between HLA-B27 and HLA-B60. In consistence with the Floris A van Gaalen et al (2012) study, our study confirmed that HLA-B60 can be used as an independent risk factor for AS susceptibility. In addition, HLA-B60 showed a modest positive biological interaction effects with HLA-B27. However, the difference between two studies is that our results showed that the risk ratio attributed by HLA-B27 is greater than that of HLA-B60 suggesting that HLA-B27 remains the most important genetic predictor on AS susceptibility in Taiwanese population. Comparatively, HLA-B60 plays as a minor additive role. Because of the difficulties in early diagnosis of AS in Taiwan, our study revealed a possibility to the implementation of combining HLA-B60 with HLA-B27 screen in future clinical practice. There are some limitations in this study. First, larger sample size is needed to confirm our finding about the interaction effect between HLA-B27 and HLA-B60. Second, the mechanisms for addressing the epistatic effects between HLA-B27 or HLA-B60 is still unclear. Third, the interaction between genes and environment is not further investigated in this study. Despite the strong correlation between HLA-B27 and HLA-B60 to the AS susceptibility was found, none of significant correlation between HLA-B27, HLA-B60 and clinical manifestations of AS, i.e. BASDAI, BASFI, and BAS-G [2] was observed in this study. Indeed, similar findings were observed in macrophage migration inhibitory factor (MIF) gene polymorphism. MIF is associated with the susceptibility but not severity of polyarthritis [22]. In short, HLA-B27 and HLA-B60 are strong genetic determinant of susceptibility to AS. Therefore, combination of these two HLA antigens can be applied as a better clinical tool to detect the risk of AS. In summary, we revealed that HLA-B60 is an independent risk factor for AS in Taiwanese population. In addition, a trend of positive interaction effects of HLA-B27 (rs13202464) and HLA-B60 was identified in a Taiwanese population, which is consistence with Caucasians population. Furthermore, we have shown that polymorphism between HLA-B27 and HLA-B60 antigens are associated with susceptibility to, but not severity of AS. As a results, Taiwanese individuals with the HLA-B27+/HLA-B60+ genotype have high risk of developing AS.
  22 in total

Review 1.  Polymorphism of HLA-B27: 105 subtypes currently known.

Authors:  Muhammad Asim Khan
Journal:  Curr Rheumatol Rep       Date:  2013-10       Impact factor: 4.592

Review 2.  Molecular biology of the HLA-B27 locus.

Authors:  E H Weiss; K Bloemer; C Doerner; W Kuon; M Lang; H Pohla; M Schattenkirchner; G Riethmüller
Journal:  Br J Rheumatol       Date:  1988

3.  Ankylosing spondylitis and HL-A 27.

Authors:  D A Brewerton; F D Hart; A Nicholls; M Caffrey; D C James; R D Sturrock
Journal:  Lancet       Date:  1973-04-28       Impact factor: 79.321

4.  High association of an HL-A antigen, W27, with ankylosing spondylitis.

Authors:  L Schlosstein; P I Terasaki; R Bluestone; C M Pearson
Journal:  N Engl J Med       Date:  1973-04-05       Impact factor: 91.245

5.  Peptide motifs of HLA-B58, B60, B61, and B62 molecules.

Authors:  K Falk; O Rötzschke; M Takiguchi; V Gnau; S Stevanović; G Jung; H G Rammensee
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

Review 6.  Clinical, epidemiologic, and therapeutic aspects of ankylosing spondylitis.

Authors:  J T Gran; G Husby
Journal:  Curr Opin Rheumatol       Date:  1998-07       Impact factor: 5.006

7.  Clonal analysis of alloreactive T cell responses against the closely related B*2705 and B*2703 subtypes. Implications for HLA-B27 association to spondyloarthropathy.

Authors:  D López; R García-Hoyo; J A López de Castro
Journal:  J Immunol       Date:  1994-06-01       Impact factor: 5.422

8.  The structure of HLA-B27 reveals nonamer self-peptides bound in an extended conformation.

Authors:  D R Madden; J C Gorga; J L Strominger; D C Wiley
Journal:  Nature       Date:  1991-09-26       Impact factor: 49.962

9.  HLA-B60 and B61 are strongly associated with ankylosing spondylitis in HLA-B27-negative Taiwan Chinese patients.

Authors:  J C C Wei; W C Tsai; H S Lin; C Y Tsai; C T Chou
Journal:  Rheumatology (Oxford)       Date:  2004-04-27       Impact factor: 7.580

10.  Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitis.

Authors:  Christina Duftner; Christian Goldberger; Albrecht Falkenbach; Reinhard Würzner; Barbara Falkensammer; Karl P Pfeiffer; Elisabeth Maerker-Hermann; Michael Schirmer
Journal:  Arthritis Res Ther       Date:  2003-07-16       Impact factor: 5.156

View more
  8 in total

1.  Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis: a meta-analysis.

Authors:  Hai Lin; Yi-Zhen Gong
Journal:  Rheumatol Int       Date:  2017-05-19       Impact factor: 2.631

Review 2.  Spondyloarthritis in North Africa: an update.

Authors:  Samy Slimani; Wafa Hamdi; Kawtar Nassar; Asgar Ali Kalla
Journal:  Clin Rheumatol       Date:  2021-02-09       Impact factor: 2.980

3.  HLA class I and II alleles in susceptibility to ankylosing spondylitis.

Authors:  John D Reveille; Xiaodong Zhou; MinJae Lee; Michael H Weisman; Lin Yi; Lianne S Gensler; Hejian Zou; Michael M Ward; Mariko L Ishimori; Thomas J Learch; Dongyi He; Mohammad H Rahbar; Jiucun Wang; Matthew A Brown
Journal:  Ann Rheum Dis       Date:  2018-10-19       Impact factor: 19.103

Review 4.  HLA associations in inflammatory arthritis: emerging mechanisms and clinical implications.

Authors:  Robert Busch; Simon Kollnberger; Elizabeth D Mellins
Journal:  Nat Rev Rheumatol       Date:  2019-06       Impact factor: 20.543

5.  rs657075 (CSF2) Is Associated with the Disease Phenotype (BAS-G) of Ankylosing Spondylitis.

Authors:  Wei-Chiao Chen; James Cheng-Chung Wei; Hsing-Fang Lu; Henry Sung-Ching Wong; Peng Yeong Woon; Yu-Wen Hsu; Jin-Ding Huang; Wei-Chiao Chang
Journal:  Int J Mol Sci       Date:  2017-01-03       Impact factor: 5.923

6.  Functional ERAP1 Variants Distinctively Associate with Ankylosing Spondylitis Susceptibility under the Influence of HLA-B27 in Taiwanese.

Authors:  Chin-Man Wang; Ming-Kun Liu; Yeong-Jian Jan Wu; Jing-Chi Lin; Jian-Wen Zheng; Jianming Wu; Ji-Yih Chen
Journal:  Cells       Date:  2022-08-05       Impact factor: 7.666

Review 7.  Does HLA-B27 Status Influence Ankylosing Spondylitis Phenotype?

Authors:  Amal Akassou; Youssef Bakri
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2018-01-08

8.  Ankylosing spondylitis: etiology, pathogenesis, and treatments.

Authors:  Xu Cao; Xisheng Weng; Wei Zhu; Xuxia He; Kaiyuan Cheng; Linjie Zhang; Di Chen; Xiao Wang; Guixing Qiu
Journal:  Bone Res       Date:  2019-08-05       Impact factor: 13.567

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.